Adverse balance of nitric oxide/peroxynitrite in the dysfunctional endothelium can be reversed by statins

J Cardiovasc Pharmacol. 2007 Oct;50(4):391-8. doi: 10.1097/FJC.0b013e31811f3fd0.

Abstract

Vascular endothelial dysfunction is a complex phenomenon that might be caused by a deficiency of nitric oxide (NO) and an overproduction of peroxynitrite (ONOO-). This study used a nanotechnological approach to monitor the in vitro effect of statins on the [NO]/[ONOO-] balance in normal and dysfunctional endothelial cells. NO and (ONOO-) were measured by electrochemical nanosensors in a single human umbilical vein endothelial cell (HUVEC) treated with atorvastatin or simvastatin for 24 hours in the presence or absence of 50 microg/mL oxidized-LDL. An imbalance between [NO]/[ONOO-] concentrations was used as an indicator of endothelial dysfunction and correlated with endothelial nitric oxide synthase (eNOS) expression. Ox-LDL induced dysfunction of the endothelium by uncoupling eNOS. NO concentration decreased from 300 +/- 12 to 146 +/- 8 nmol/L and (ONOO-) increased from 200 +/- 9 to 360 +/- 13 nmol/L. The [NO]/[ONOO-] balance decreased from 1.50 +/- 0.04 (control) to 0.40 +/- 0.03 for cells co-incubated with ox-LDL. Treatment with statins reversed eNOS uncoupling, induced by oxidized-LDL and significantly increased the [NO]/[ONOO-] balance to 1.2 +/- 0.1. These results demonstrate that statins can restore endothelial function by increasing eNOS expression, decreasing eNOS uncoupling, reducing the (ONOO-) level (nitroxidative stress), and shifting the [NO]/[ONOO-] balance towards NO.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetophenones / pharmacology
  • Atorvastatin
  • Calcimycin / pharmacology
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism
  • Endothelium, Vascular / physiopathology
  • Enzyme Inhibitors / pharmacology
  • Heptanoic Acids / pharmacology
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Lipoproteins, LDL / pharmacology
  • NADPH Oxidases / antagonists & inhibitors
  • Nitric Oxide / metabolism*
  • Nitric Oxide Synthase Type III / metabolism
  • Peroxynitrous Acid / metabolism*
  • Pyrroles / pharmacology
  • Simvastatin / pharmacology

Substances

  • Acetophenones
  • Enzyme Inhibitors
  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipoproteins, LDL
  • Pyrroles
  • oxidized low density lipoprotein
  • Peroxynitrous Acid
  • Nitric Oxide
  • Calcimycin
  • Atorvastatin
  • Simvastatin
  • acetovanillone
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III
  • NADPH Oxidases